277 related articles for article (PubMed ID: 29707993)
1. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma.
Trimboli P; Lauretta R; Barnabei A; Valabrega S; Romanelli F; Giovanella L; Appetecchia M
Int J Biol Markers; 2018 May; 33(2):156-160. PubMed ID: 29707993
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules.
Giovanella L; Imperiali M; Piccardo A; Taborelli M; Verburg FA; Daurizio F; Trimboli P
Eur J Clin Invest; 2018 Jun; 48(6):e12934. PubMed ID: 29635700
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
4. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.
Karagiannis AK; Girio-Fragkoulakis C; Nakouti T
Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
6. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
7. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
9. Radioguided hepatic resection with
López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
[TBL] [Abstract][Full Text] [Related]
10. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
11. Can procalcitonin be useful for medullary thyroid cancer?
Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
15. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD; Hoang TD; Shakir MKM
Oncology; 2021; 99(7):422-432. PubMed ID: 33878761
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules.
Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L
Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of calcitonin and procalcitonin Elecsys
Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L
Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633
[TBL] [Abstract][Full Text] [Related]
19. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
20. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
